VIDAR-1
VIDAR-1 is a phase 1/2 master protocol for open-label, multi-centre, single-arm sub-studies, first in human clinical studies of TCR-T therapy (autologous TCR-modified T-cell Therapy) targeting mutated Kirsten rat sarcoma (mutKRAS) administered in metastatic or locally advanced Pancreatic Ductal Adenocarcinoma (PDAC) adult patients with specific mutKRAS and Human Leukocyte Antigen (HLA) genotypes. ANOC-001 is the first product within this clinical trial.
Patient information
If you are a patient and interested in participating in Anocca’s clinical trial, please speak to your treating physician. You and your healthcare provider can learn more about this trial by visiting here.